CURE’s 2018-2019 research initiative includes the following studies:
Research
Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta
Douglas Graham, MD, PhD
Aflac Cancer Center Precision Medicine Program
Kavita Dhodapkar, MD
Precision Cellular Immunotherapy of High-risk Glioma in Children
Kelly Goldsmith, MD
Optimizing Chemoimmunotherapy with DFMO in Relapsed and Refractory Neuroblastoma
Lisa Ingerski, PhD
Health Related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of Refractory or Progressive Pediatric Brain Tumors
Lubing Gu, MD
Development of Dual Inhibitors of MDM2 and XIAP for Treatment of Childhood Cancers
Robert Schnepp, MD, PhD
BMI1 as an Oncogenic Driver and Novel Target in Alveolar Rhabdomyosarcoma
Tobey MacDonald, MD
Employing Focused Ultrasound to Aid Therapeutic Delivery to Pediatric Brain Tumors
Tobey MacDonald, MD
Phase I Trial of WP1066 in Children with Refractory and Progressive Malignant Brain Tumors with Evidence of JAK2/STAT3 Pathway Activation
Baylor College of Medicine
Alexandra Stevens, MD
A Trial of Atovaquone with Conventional Chemotherapy for Pediatric AML (ATACC AML)
Lisa L. Wang, MD
Optimizing GD2.CAR T Cell Immunotherapeutic Strategies for Relapsed Osteosarcoma and Neuroblastoma
Children’s Cancer Therapy Development Insitute
Charles Keller, MD
Prediction & Validation of a Novel Drug Combination Against Anaplastic Wilms’ Tumor
Children’s Hospital of Philadelphia
Frank M. Balis, MD
GD2 as a Circulating Tumor Biomarker and Clinical Trial Endpoint for Neuroblastoma
Michael Chorny, PhD
Targeted Neuroblastoma Pharmacotherapy Using Nanocarriers
Children’s Oncology Group and Fred Hutchinson Cancer Reserach Center
Soheil Meshinchi, MD, PhD
Target Pediatric AML
